Transdermal Fibronectin (TFNpro) is a multifunctional humanized recombinant macromolecular glycoprotein fused with University of Science and Technology of China (USTC) transdermal technology. Produced via high-density yeast fermentation with purity exceeding 95%, it displays superior bio-stability and physiological activity.
The molecule retains the essential human RGD cell-adhesion motif, achieving a 10-fold absorption enhancement when guided by transdermal cyclic peptides. It specifically directs keratinocyte migration to micro-stressed sites, accelerating stratum corneum physical barrier assembly and moisture retention to visibly soothe sensitivity, dryness, and barrier compromise.
Tissue Repair Data
TFNpro transdermal fibronectin permeation rate and epidermal barrier reconstruction data.
RAW MATERIAL TECHNICAL & REGULATORY DOSSIER
Comprehensive Technical, Quality Specification, and Regulatory Dossier for R&D Formulators, Procurement, and Product Managers
📊
Biotechnology Mechanism & Scientific Evidence
Authoritative Brochure Technical Diagram · Molecular Model · Transdermal & Efficacy Mechanism
Mechanism DiagramTFNpro transdermal fibronectin: 8-fold enhanced absorption and stratum corneum barrier repair histological evidence.
🔬
Formulation R&D Engineer Guide (R&D Technical Dossier)
Formulation Application · Physicochemical Parameters · Stability & Compatibility
| INCI Name (CN) |
Decapeptide-4、Fibronectin、1,2-1,2-Hexanediol, Aqua |
INCI Name (EN) |
Decapeptide-4, Fibronectin, 1,2-Hexanediol, Aqua |
| CAS No. |
917094-11-2 / 86088-83-7 / 6920-22-5 / 7732-18-5 |
Recommended Dosage |
0.2% - 2.0%（ Repair 0.5% - 1.0%） |
| Optimal pH Range |
6.0 - 7.2 |
Thermal Processing |
Add below 42°C during gentle mixing phase |
| Appearance & Odor |
Clear colorless liquid, odorless |
Solubility & Method |
Easily miscible with aqueous phase and hydrogels |
💡 Compatibility Guidelines & Precautions: Compatible with non-ionic polymers, hyaluronic acid, and ceramides; avoid strong cationic surfactants
📦
Procurement & Compliance Dossier (Procurement & Compliance)
NMPA Code · MOQ · Sampling Support · Certificate of Analysis
| NMPA Submission Code |
✓ 194980-00075-3074 |
Supply Packaging |
1kg/fluorinated bottle, 5kg/drum, 25kg/drum |
| Minimum Order Quantity (MOQ) |
1 kg (Ready Stock) |
Delivery Lead Time |
Dispatched within 24-48 hours |
| Storage Conditions |
Store refrigerated at 2-8°C, dark and sealed |
Shelf Life (Shelf Life) |
24 Months |
| R&D Sample Support |
Complimentary 30g trial sample with formulation recommendations |
Quality Documentation |
Batch COA, SDS, TDS, Cell Migration & Safety Reports |
💡
Product Planning & Marketing Highlights (Marketing Highlights)
Core Mechanism · Efficacy Claims · Recommended Formats · Scientific Backing
🧬 Core Bio-Tech Barrier & Mechanism of Action:
Contains authentic RGD cell-adhesion motifs that bind integrin alpha5beta1 on epidermal and dermal cells, triggering focal adhesion kinase (FAK) signaling to stimulate keratinocyte migration and rapid wound/barrier healing.
✨ Key Selling Point Keywords:
🏷️ Intensive Barrier Defense🏷️ Repairing Dry Damaged Skin🏷️ Strengthening Lipid Barrier🏷️ Soothing Sensitive Redness🏷️ Plumping Elasticity & Firmness
🧴 Recommended Product Formats & Categories:
Barrier rescue ampoules, sensitive skin soothing lotions, post-procedure repair gels, micro-needling serums
📜 Patented Technologies & Scientific Backing:
US and Chinese Invention Patents on Transdermal Recombinant Fibronectin Peptides
⚖️
Regulatory Compliance & Peer-to-Peer Disclaimer
Regulatory & Professional Compliance Statement:
1. The raw material characteristics and experimental data (including cytological studies, mechanism diagrams, and literature citations) presented on this webpage are intended exclusively for technical discussion and formulation R&D reference by cosmetic brand formulators, R&D engineers, product planners, and academic research institutions. They do not constitute finished consumer cosmetic efficacy claims or commercial warranties.
2. Pursuant to the Regulations on the Supervision and Administration of Cosmetics, Standards for Cosmetic Efficacy Claim Evaluation, and relevant global cosmetic regulatory frameworks, cosmetic brand enterprises utilizing this raw material shall be solely responsible for the safety, stability, and efficacy claims of their finished consumer products, and shall independently complete efficacy evaluations and regulatory filings/registrations with the competent health authorities prior to commercial launch. Conclusions from in-vitro or cellular studies shall not be directly extrapolated as consumer claims.
3. Mellgen Biotech assumes no joint or indirect liability for any claims or regulatory non-compliance arising from improper customer formulation, unauthorized off-label claims, or unverified applications.
